We would like to inform all participants, speakers, and attendees that the ICPOC 2026 event scheduled during November 23-25, 2026 in Singapore and Online has been postponed. The decision has been made to ensure the best possible experience for everyone involved. The new dates will be announced soon and updated on our website. We sincerely appreciate your understanding and continued support.
For any queries, please contact: [email protected]
We are excited to bring you an even bigger and better event!
Please stay tuned for updated details, which will be shared soon.
The Second Affiliated Hospital of Kunming Medical University, China
The purpose of this investigation was to develop and validate a risk model based on natural killer (NK) cell-associated lncRNAs to predict outcomes in individuals with hepatocellular carcinoma (HCC). To further explore the role of NK cells in the HCC tumor microenvironment, we leveraged single-cell RNA sequencing data and the TCGA-LIHC dataset to identify NK cell-associated lncRNAs. Using Cox regression and LASSO techniques, we pinpointed four key lncRNAs as prognostic markers for the model. The model demonstrated robust predictive power across the training set, validation set, and entire dataset. Additionally, we identified a synergistic interaction between NK cells and other immune cells, particu¬larly CD8 + T cells, in HCC. Moreover, we uncovered novel molecular subgroups of HCC and their associations with the immune microenvironment and drug sensitivity. To further validate these findings, we performed experimental validation of the expression and function of the model lncRNAs in HCC. These results suggest that the NK cell-associated lncRNA model not only serves as an effective prognostic tool for HCC patient outcomes but also offers potential molecular targets for immunotherapy and targeted therapies.
Jinze Li is a doctor. candidate in Gastrointestinal Surgery at Kunming Medical University, with clinical experience as a surgeon and a strong background in translational research. He has published multiple SCI papers as first author, co-first author, and co-corresponding author in journals such as Advanced Science and Frontiers in Immunology. His research focuses on immune mechanisms, lncRNA signatures, and metabolic reprogramming in digestive system tumors. He also holds one patent and is committed to integrating basic research with clinical practice
© 2026 Mathews International LLC. All rights reserved.